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Case Report
Squamous cell carcinoma ofthe bladder and prostatic
urethra in a post renal transplant patient
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Carcinoma arising in the bladderfollowing renal
transplantation is extremely rare. We present a
case of squamous cell carcinoma of the bladder
and prostatic urethra in a post renal transplant
patientanddiscusstheliteratureandmanagement
issues.
Immuno-suppressive treatments for
transplantation interfere with host immunity
predisposingtoavarietyofmalignancies.' Lower
urinarytracttumours areveryrareaccounting for
only 2% of these malignancies.2
CASE REPORT An 80-year old male non-
smoker who had undergone cadaveric renal
transplantation for end-stage renal disease three
yearspreviouslypresentedwithirritativevoiding
symptoms and microscopic haematuria. His
immunosuppressionincludedcyclosporinforone
yearandtacrolimus subsequently. 27yearsearlier
he had undergone a left Orchidectomy for
testicular seminorna and radiotherapy for para-
aortic nodes. He was found to have microscopic
haematuria six months following the
Fig 1. Squamous cell carcinoma at the bladder neck
(Magnification X 30).
Fig 2. Infiltrating squamous cell carcinoma
(Magnification X 120).
transplantation, cystoscopywasnormal. Flexible
cystoscopy on current presentation showed
yellowishtissueatthebladderneck. Hedeveloped
acuteurinaryretentionfollowingthisexamination
and underwent trans-urethral resection of this
tissue in the bladder neck and prostatic urethra.
Histological examination revealed moderate to
poorly differentiated squamous cell carcinoma at
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the bladder neck infiltrating the prostate with
squamousmetaplasiaanddysplasiaintheadjacent
urothelium (figs. 1, 2). Because of patient's age
and co-morbidity, radical cystectomy was
deferredandfurtherpalliativeresectionwasdone
allowing successful voiding. He is currently
maintained on low dose tacrolimus.
DISCUSSION
Hostimmunityisoneofthewell-knownprotective
factors against carcinogenesis and
immunosuppression interferes with this host
ability. Rao and Anderson observed a 25%
incidence of tumours during the second decade
after transplantation.1 Of newly diagnosed
tumoursinorganallograftrecipients,2%originate
in the lower urinary tract according to the data
from the Cincinnati transplant tumour registry.2
There are few case reports of de-novo bladder
carcinoma inrenal allograftrecipients. The most
commontype is transitional cell carcinoma, with
squamous cell carcinoma being relatively
rare.3'4'56 Cyclophosphamide and azathioprine
have been implicated in the aetiology ofbladder
cancer.7 8
The management of this tumour poses specific
problems. Radical surgery would be needed in
patients with high-grade invasive tumours. One
shouldconsiderfateoftheallograftandoptionof
reconstructingreservoirorconduitforsalvageable
graft. Graft removal may be necessary to avoid
the immunosuppression totally. An alternative
option would be to modify immunosuppression
such as discontinuing cyclophosphamide or
reducing the dose ofotherimmunosuppressants.
There is no recognised standard approach and
management should be tailored to the patient's
medical condition in a multidisciplinary setting.
In our patient, the only identifiable risk factor is
immunosuppression with tacrolimus and he has
not been treated with cyclophosphamide. His
immunosuppression is maintained with low dose
tacrolimus withoutcompromisinggraftfunction.
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